United Kingdom· GB-APID-5235811000001100
Lederkyn 500mg tablets
A sulfamethoxypyridazine product containing sulfamethoxypyridazine, registered in United Kingdom by Wyeth Pharmaceuticals.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Sulfamethoxypyridazine
- Manufacturer
- Wyeth Pharmaceuticals
- Country
- United Kingdom (GB)
- ATC code
- J01ED05
- ATC class
- Sulfamethoxypyridazine
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J01ED05
Sulfamethoxypyridazine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a56820de-c98f-4e6c-9687-2412d6e82a2d GET /v1/drugs/a56820de-c98f-4e6c-9687-2412d6e82a2d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "5235811000001100",
"desc": "Lederkyn 500mg tablets (Wyeth Pharmaceuticals)",
"form": "Oral tablet",
"vpid": "5241611000001103",
"source": "dmd",
"vtm_id": "777643007",
"strength": "500 mg",
"substance": "Sulfamethoxypyridazine",
"ingredient": "Sulfamethoxypyridazine",
"supplier_code": "2092401000001109"
}See everything about sulfamethoxypyridazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.